RxDoctor Payments Data

Anne Lafontant, MD

General Practice · Kissimmee, FLNPI 1518361377

Payments from drug & device makers

$2,247in general payments, 2019–2025

Across 62 payments — averaging $36.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$214
  • GSK$189
  • Medtronic$154
  • Boehringer Ingelheim$153
  • Bayer$149
  • plus $358 from 8 others

What the payments were for

  • Food & beverage$2,247100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,247 in reported general payments places this provider in the 90th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$6,280
Medicare patients
26
Services billed
90

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$130,049
TrulicityDulaglutide63$114,171
JardianceEmpagliflozin67$95,701
EliquisApixaban57$78,976
FarxigaDapagliflozin Propanediol58$73,615
MounjaroTirzepatide20$51,462
LinzessLinaclotide53$49,673
JanuviaSitagliptin Phosphate40$46,606
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$29,426
EntrestoSacubitril/Valsartan15$28,131
XareltoRivaroxaban18$28,002
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$16,252
JanumetSitagliptin Phos/Metformin Hcl14$15,494
Lantus SolostarInsulin Glargine,hum.Rec.Anlog73$11,571
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$9,605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$143$165,63383 claims
Novo NordiskOzempic$214$130,04985 claims
Boehringer IngelheimJardiance, Stiolto Respimat$153$100,76778 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,030$89,86876 claims
PfizerEliquis$38$78,97657 claims
MerckJanuvia, Janumet$22$62,10054 claims
AbbVieLinzess, Synthroid$21$51,28065 claims
GSKTrelegy Ellipta$189$29,42632 claims
NovartisEntresto$34$28,13115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,901 general practice providers in Florida.

Other general practice in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →